BridgeBio Pharma, Inc. - 8-K Filing
FDA accepted and granted Priority Review for BridgeBio's NDA of oral infigratinib for children with achondroplasia, with a PDUFA date set for February 4, 2027. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $BBIO